Patents by Inventor A. Scott Muerhoff

A. Scott Muerhoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-B-CORONAVIRUS ANTIBODY IN A SAMPLE
    Publication number: 20230258638
    Abstract: Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of ?-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-?-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject.
    Type: Application
    Filed: October 12, 2022
    Publication date: August 17, 2023
    Inventors: A. Scott Muerhoff, John C. Prostko, James L. Stewart, Mary A. RODGERS, Gavin A. CLOHERTY, James Hartnett, Jeff Moore, Kathy Otis, Alak Kar, Bailin Tu, Bryan Tieman, Carolyn Strobel, David Hawksworth, Robert Ziemann, Zhihong Lin, Chris Marohnic, Peter Wiebe, Todd Meyer, Weijie Jiao, Gangamani S. Beligere, Saminathan X. Muthusamy, Jessica L. Grieshaber, Sandra K. Pearce, Edwin C. Frias, Russell E. Taylor, Kelly Coller, Yangrong E. Zhang, Thomas T. Biegalski, David J. Daghfal, Claudio Galli, Sergey Y. Tetin, Qiaoqiao Ruan, Patrick MacDonald, Michael S. Cassidy, Mary E. Gardiner, Mary Ann P. Palafox, Matthew S. Matias, Melissa B. Brennan, Philip W. Schultz, Beth C. Trudeau
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 11428694
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: August 30, 2022
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • METHODS AND KITS FOR DETECTING SARS-COV-2 PROTEIN IN A SAMPLE
    Publication number: 20220043000
    Abstract: Disclosed herein are methods, kits, and systems relates for detecting the presence or determining the amount of SARS-CoV-2 nucleocapsid protein in one or more samples obtained from a subject.
    Type: Application
    Filed: August 4, 2021
    Publication date: February 10, 2022
    Inventors: A. Scott Muerhoff, Toru Yoshimura, Philip M. Hemken, Eitan Israeli, Ryotaro Chiba, Takamitsu Morikawa, Dong Wang, Fusamitsu Yanagihara
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20210231665
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200141937
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: May 24, 2019
    Publication date: May 7, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200033344
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10444242
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 15, 2019
    Assignees: ABBOTT LABORATORIES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10345311
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 10197573
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 5, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV antigen-antibody combination assay and methods and compositions for use therein
    Patent number: 9841427
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 12, 2017
    Assignee: Abbott Laboratories
    Inventors: George J. Dawson, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko, M. Felicia Bogdan, Christopher C. Marohnic
  • HCV NS3 RECOMBINANT ANTIGENS AND MUTANTS THEREOF FOR IMPROVED ANTIBODY DETECTION
    Publication number: 20170327803
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, M. Felicia Bogdan, Robin Gutierrez
  • HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
    Patent number: 9790478
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 17, 2017
    Assignee: Abbott Laboratories
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, M. Felisha Bogdan, Robin Gutierrez
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052184
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS, ANDREA BRANCH, FRANCIS ENG
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052183
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS
  • Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
    Patent number: 9551714
    Abstract: A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: January 24, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Thomas P. Leary, Robin A. Gutierrez, A. Scott Muerhoff, George J. Dawson, Suresh M. Desai, Dinesh Shah
  • HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN
    Publication number: 20170003290
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Application
    Filed: September 11, 2015
    Publication date: January 5, 2017
    Inventors: GEORGE J. DAWSON, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko, M. Felicia Bogdan, Christopher C. Marohnic
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20160291020
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: March 23, 2016
    Publication date: October 6, 2016
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 9371374
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 21, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN
    Publication number: 20160123983
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Application
    Filed: September 11, 2015
    Publication date: May 5, 2016
    Inventors: GEORGE J. DAWSON, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko
  • HCV antigen-antibody combination assay and methods and compositions for use therein
    Patent number: 9194873
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: November 24, 2015
    Assignee: ABBOTT LABORATORIES
    Inventors: George J. Dawson, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko